UNSPSC 51152047: Suxethonium

This classification denotes a muscle relaxant with the molecular formula C16H34N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MED638SZQB, chemically known as succinic acid, diester with choline iodide but generally known as suxethonium, which bears US NIH Compound Identifier 71732. European Medicines Agency schedules Suxethonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15440MIG. The term SUXETHONIUM is an International Non-Proprietary Name.

As of Q4 2014, SUXETHONIUM remains the US FDA Preferred Term for this commodity. Suxethonium bears US NLM identifiers UMLS ID C0605824 and NCI Concept Code C87315. SMILES: CC[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)CC.[Cl-].

UNSPSC 51152047 Suxethonium is a Commodity code whose recent state and local opportunities reflect procurement of emergency medical and pharmaceutical products rather than the specific drug its nominal title suggests. Seminole County, Florida has solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive IFB, while the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer prescription fulfillment models for state employee health plans. The issuing bodies span county health departments and state HHS agencies, indicating demand across local public health infrastructure and state-level pharmacy benefit administration. Recent activity shows state and local governments procuring both emergency-response pharmaceuticals for community health initiatives and exploring vendor capacity for large-scale, direct prescription sourcing outside traditional pharmacy benefit manager channels.

Activity appears concentrated in the Southeast and Southwest, with recent opportunities from Florida and Texas. Seminole County's IFB (No. IFB60459723LAS, due July 26, 2023) sought quarterly deliveries of Naloxone and drug deactivation systems to its Community Health Building in Sanford with fixed-fee pricing and a two-year initial term plus one-year renewal option; the procurement included FEMA-potential funding and standard compliance requirements (drug-free workplace, E-Verify, workers' compensation and liability insurance). The Texas HHS Commission's RFI (No. HHS0017013, posted April 3, 2026) represented early-stage market research into direct contracting capabilities rather than a formal competitive solicitation, seeking vendor experience with self-insured employer and government health plan prescription fulfillment outside GPO and PBM arrangements. Neither opportunity specified set-asides for disadvantaged enterprises, and neither disclosed award amounts.